ARTICLES BY TYLER MENICHIELLO
-
![GettyImages-1295693748-mRNA]( "Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases")
Developing Bespoke Antisense Oligonucleotides To Treat Rare Diseases11/26/2024EveryONE Medicines CEO, Kent Rogers, explains the company’s mission to address a major unmet need in children with rare neurodegenerative diseases, one patient at a time.
-
![Decisions ahead road sign-GettyImages-1131216270]( "Tune Therapeutics On Clinical Readiness, Technology Adoption")
Tune Therapeutics On Clinical Readiness, Technology Adoption10/18/2024Heidi Zhang, Ph.D., explains Tune Therapeutics' epigenetic approach to gene therapy and how the company is preparing its lead candidate for the clinic, as well as it's modular approach to automation.
-
![GettyImages-1480892977-doctor-gene-dna-brain-lungs-heart]( "How Platform Technologies Are Shaping The Gene Therapy Landscape")
How Platform Technologies Are Shaping The Gene Therapy Landscape10/18/2024Leading experts in gene therapy discuss CMC strategy for platform technologies, product lifecycle management, and the role CDMOs play in moving the space forward.
-
![Developing mRNA Vaccines GettyImages-1307593959]( "RNA Vaccines: Just Scratching The Surface")
RNA Vaccines: Just Scratching The Surface12/28/2023RNA vaccines have shown promise in preventing infectious diseases and treating cancer, but clinical development varies markedly between the two. HDT Bio’s Dr. Berglund discusses this and how they can be improved.
-
![Genetic engineering-GettyImages-1439151595]( "Base Editing And Prime Editing: How They're Changing Gene Therapy")
Base Editing And Prime Editing: How They're Changing Gene Therapy9/27/2023I spoke to Beam Therapeutics and Prime Medicine to learn about base editing and prime editing and how they're advancing gene therapies.
-
![Crispr gene editing-GettyImages-1139760176]( "Excision BioTherapeutics' CSO Discusses Dual-Guide RNA's Impact On Gene Editing")
Excision BioTherapeutics' CSO Discusses Dual-Guide RNA's Impact On Gene Editing9/15/2023Excision BioTherapeutics' CSO, Dr. TJ Cradick, explains Excision's dual-guide RNA approach to cure chronic, viral infectious diseases.
Tyler Menichiello
Tyler Menichiello is a contributing editor to Bioprocess Online, Cell & Gene, and Clinical Leader. He interviews executives and subject matter experts across the biopharma industry to write about their successful approaches in biologics development from pre-IND planning all the way through trial design, manufacturing, and commercialization. He aims to investigate the industry’s most prevalent challenges and emerging best practices to provide both interesting and actionable content for industry leaders. Prior to writing for Life Science Connect, Tyler spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, where he worked on clinical trials involving hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can email Tyler at tyler.menichiello@lifescienceconnect.com, or visit his LinkedIn profile.